- Home
- NC vs RIGL Comparison
NC vs RIGL Comparison
Compare NC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NC
- RIGL
- Stock Information
- Founded
- NC 1913
- RIGL 1996
- Country
- NC United States
- RIGL United States
- Employees
- NC N/A
- RIGL N/A
- Industry
- NC Coal Mining
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- NC Energy
- RIGL Health Care
- Exchange
- NC Nasdaq
- RIGL Nasdaq
- Market Cap
- NC 291.5M
- RIGL 335.5M
- IPO Year
- NC N/A
- RIGL 2000
- Fundamental
- Price
- NC $41.25
- RIGL $34.98
- Analyst Decision
- NC
- RIGL Buy
- Analyst Count
- NC 0
- RIGL 5
- Target Price
- NC N/A
- RIGL $38.20
- AVG Volume (30 Days)
- NC 8.1K
- RIGL 728.5K
- Earning Date
- NC 10-29-2025
- RIGL 11-06-2025
- Dividend Yield
- NC 2.48%
- RIGL N/A
- EPS Growth
- NC N/A
- RIGL N/A
- EPS
- NC 4.23
- RIGL 5.43
- Revenue
- NC $265,880,000.00
- RIGL $267,921,000.00
- Revenue This Year
- NC N/A
- RIGL $59.93
- Revenue Next Year
- NC N/A
- RIGL N/A
- P/E Ratio
- NC $9.64
- RIGL $6.43
- Revenue Growth
- NC 27.25
- RIGL 105.62
- 52 Week Low
- NC $25.52
- RIGL $13.37
- 52 Week High
- NC $45.50
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- NC 58.79
- RIGL 50.83
- Support Level
- NC $39.40
- RIGL N/A
- Resistance Level
- NC $41.76
- RIGL $38.13
- Average True Range (ATR)
- NC 1.25
- RIGL 2.13
- MACD
- NC 0.30
- RIGL -2.47
- Stochastic Oscillator
- NC 87.25
- RIGL 82.02
About NC NACCO Industries Inc.
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments that are coal mining, North American mining (NA mining), and minerals management. The majority of its revenue is from the coal mining segment. This segment operates surface coal mines under long-term contracts with power generation companies and an activated carbon producer pursuant to a service-based business model. The NA mining segment provides value-add contract mining and services for producers. Minerals management generates income from royalty-based leases by acquiring and promoting oil, gas, and coal mineral interests. The company is diversifying beyond coal mining due to political and economic pressures associated with carbon emissions.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.